Technical Name Bi-specific antibodiesuses thereof
Project Operator Kaohsiung Medical University
Project Host 鄭添祿
We developed a humanized bifunctional antibody (mPEG×tumor marker),the anti-PEG end can be non-covalently modified to bind any PEGylated nano-druga contrast agent by one-step "formulation". The non-covalent binding solved the problems of chemical modification such as the masking of the antibody binding site, heterogeneity, drug instability. The other end of the bifunctional antibody can specifical
Scientific Breakthrough
1."One-step formulation" non-covalent bond modification combined with any PEGylated nanomolecule
2. Non-covalent bond modification solved the problems caused by chemical modification, such as masking antibody epitope, heterogeneity,drug instability after modification.
3. Specific target cancer metastasis cancer for treatment
4. Can be replaced with different cancer targetsdrug accumulation for all
Industrial Applicability
1. The convenience use of clinical modification method by "one step formulation"
2. Can be applied to all PEGylated nano-drugscontrast agents
3. Diversity of tumor targets (personalized medicine)
4. "Humanized" bifunctional antibodies meet FDA standardscould accelerate the clinical trial processesreduce the research costs.
Keyword Methoxy-PEGylated nanoparticles (mPEG-NPs) Bispecific antibodies (BsAb) mPEGylated liposomal doxorubicin (PLD) Noncovalent modification Targeted therapy One-step mixing Nano-image probes mPEG×HER2/EGFR/EphA2 Endocytosis Changeable
  • Contact